PR
PRPO.US Precipio Inc
- Market cap
- USD 33.8M
- P/E
- -
- P/B
- 2.67x
- ROE
- -15.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PRPO.US undervalued?
Graham numberThe Graham number of Precipio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Precipio Inc fundamental analysis
No fundamental analysis for Precipio Inc yet.
Precipio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc…
Full company profilePrecipio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Precipio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.56M | 1.72M | 2.86M | 3.13M | 6.09M | 8.85M | 9.41M | 15.2M | 16.0M | 24.0M | 27.5M |
| Gross Profit | -205K | 292K | 225K | 219K | 1.15M | 2.39M | 2.51M | 6.02M | 7.56M | 10.7M | 12.3M |
| Operating Income | -7.82M | -15.5M | -13.9M | -11.0M | -9.15M | -9.61M | -12.8M | -7.62M | -4.22M | -1.20M | -2.70M |
| EBITDA | -1.60M | -5.45M | -7.96M | -7.99M | -7.79M | -7.05M | -10.6M | -4.32M | -2.70M | 1.46M | -947K |
| Net Income | -7.62M | -20.7M | -15.7M | -13.2M | -10.6M | -8.55M | -12.2M | -5.85M | -4.29M | -363K | -2.23M |
| EPS | -158,667 | -1,338 | -218 | -47 | -13 | -8.10 | -11 | -4.51 | -2.93 | -0.23 | -1.24 |
| Balance Sheet | |||||||||||
| Total Assets | 1.26M | 27.3M | 21.6M | 19.5M | 20.7M | 30.4M | 21.5M | 18.1M | 17.0M | 21.3M | 21.7M |
| Total Liabilities | 20.6M | 14.2M | 15.5M | 6.31M | 6.55M | 5.84M | 5.14M | 3.67M | 4.90M | 6.76M | 6.85M |
| Shareholders' Equity | -19.4M | 13.0M | 6.12M | 13.2M | 14.1M | 24.6M | 16.3M | 14.4M | 12.1M | 14.6M | 14.9M |
| Cash & Short-term Investments | 110K | 421K | 381K | 848K | 2.66M | 11.7M | 3.45M | 1.50M | 1.39M | 6.04M | 3.58M |
| Total Debt | 7.98M | 3.58M | 5.11M | 1.36M | 1.49M | 1.43M | 1.39M | 1.12M | 1.25M | 3.65M | 3.69M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.55M | -6.69M | -6.75M | -9.14M | -7.43M | -6.58M | -7.72M | -3.56M | 439K | 685K | 1.78M |
| Capital Expenditure | 19.0K | 143K | 97.0K | 55.0K | 151K | 682K | 277K | 126K | 223K | 326K | 317K |
| Free Cash Flow | -3.57M | -6.83M | -6.85M | -9.20M | -7.59M | -7.26M | -8.00M | -3.69M | 216K | 359K | 1.46M |
| Ratios | |||||||||||
| ROE | - | -158.9% | -256.3% | -100.3% | -75.2% | -34.8% | -74.9% | -40.6% | -35.5% | -2.5% | -15.0% |
| ROA | -604.9% | -75.9% | -72.6% | -67.9% | -51.3% | -28.1% | -56.7% | -32.3% | -25.2% | -1.7% | -10.3% |
| Net Profit Margin | -489.1% | -1,201.0% | -548.0% | -423.5% | -174.4% | -96.6% | -129.7% | -38.5% | -26.9% | -1.5% | -8.1% |
| Debt to Equity | - | 0.27x | 0.83x | 0.10x | 0.11x | 0.06x | 0.09x | 0.08x | 0.10x | 0.25x | 0.25x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Precipio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 3.73M | 13 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Sep 22, 2023.
Who owns Precipio Inc
- Insiders 12.65%
- Institutions 23.84%
- Public & others 63.51%
- Shares outstanding 1.79M
- Free float 1.41M
Top funds holding PRPO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 39.7K | 2.22% | +13.93% | Sep 2026 |
| Fidelity Extended Market Index | 8.28K | 0.46% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 4.90K | 0.27% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 3.19K | 0.18% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 2.62K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.27K | 0.13% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 1.24K | 0.07% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.10K | 0.06% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 1.01K | 0.06% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 728.00 | 0.04% | +18.57% | Sep 2026 |
| DFA US Vector Equity Class F | 548.00 | 0.03% | 0.00% | Aug 2026 |
| DFA US Core Equity Class F | 492.00 | 0.03% | 0.00% | Aug 2026 |
| Dimensional US Core Equity 2 ETF | 479.00 | 0.03% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 456.00 | 0.03% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 410.00 | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 355.00 | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Core Equity USD Acc | 315.00 | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 114.00 | 0.01% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 2 Instl | 100.00 | 0.01% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 61.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding PRPO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 46.1K | 2.57% | +81.09% | Jun 2026 |
| BlackRock Inc | 34.7K | 1.93% | +19.41% | Jun 2026 |
| Geode Capital Management, LLC | 18.7K | 1.04% | -0.64% | Jun 2026 |
| Citadel Advisors Llc | 14.7K | 0.82% | -2.66% | Jun 2026 |
| XTX Topco Ltd | 9.45K | 0.53% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 9.41K | 0.52% | +0.66% | Jun 2026 |
| UBS Group AG | 343.00 | 0.02% | +51.10% | Jun 2026 |
| Wells Fargo & Co | 50.00 | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 32.00 | 0.00% | -76.81% | Jun 2026 |
| Royal Bank of Canada | 11.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 3.00 | 0.00% | 0.00% | Jun 2026 |
| IFP Advisors, LLC | 3.00 | 0.00% | 0.00% | Jun 2026 |
| FMR Inc | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 0.00 | 0.00% | -100.00% | Sep 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Sep 2026 |
| Evernest Financial Advisors LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Topline Capital Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Precipio Inc company profile
- Company name
- Precipio Inc
- Ticker
- PRPO.US
- Exchange
- USA Stocks
- Listed since
- Jul 18, 2000
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 61
- Fiscal year end
- December
- Address
- 4 Science Park, New Haven, CT, United States, 06511
- Phone
- 203 787 7888
- Website
- precipiodx.com
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Precipio Inc management
5- Mr. Ilan DanieliFounder, President, CEO & Director · born 1972
- Mr. Ahmed Zaki SabetChief Operating Officer · born 1985
- Dr. Ayman A. Mohamed M.D.Chief Technology Officer · born 1984
- Mr. Matthew GageChief Financial Officer · born 1967
- Ms. Miri Chiko-RadomskiChief Legal Counsel & People Officer